Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

30 results about "Lymphatic metastasis" patented technology

Lymphogenous metastasis is characterized by the penetration of tumor cells into the lymphatic vessel and then by lymph flow to nearby or distant lymph nodes. Lymphogenically, epithelial cancers are more common (eg, melanoma). Tumor processes in internal organs: the stomach, colon, larynx,...

Application of luteoloside-sensitized cis-platinum in preparation of esophageal squamous cell carcinoma treatment medicine

The invention relates to an application of galuteolin-sensitized cis-platinum in preparation of a medicine for treating esophageal squamous cell carcinoma. It is found that the galuteolin can block the progress of esophageal squamous carcinoma cells in multiple links including apoptosis induction, growth and invasion inhibition and the like, the galuteolin can also significantly enhance inhibition of cis-platinum on lymphatic metastasis of esophageal squamous carcinoma cells in a mouse model, and the galuteolin and the cis-platinum have a significant synergistic effect.
Owner:BEIJING CANCER HOSPITAL PEKING UNIV CANCER HOSPITAL

Application of chrysin-sensitized cis-platinum in treatment of esophageal squamous cell carcinoma

The invention relates to application of chrysin-sensitized cis-platinum in treatment of esophageal squamous cell carcinoma. It is found that chrysin can sensitize the growth inhibition effect, invasion inhibition effect and apoptosis induction effect of cis-platinum-mediated esophageal squamous carcinoma cells in a dose-dependent manner, and can effectively enhance the growth inhibition and apoptosis promotion effect of cis-platinum-mediated tumors to inhibit the increase of the tumor volume. The inhibition of cis-platinum on lymphatic metastasis of esophageal squamous carcinoma cells is remarkably enhanced, and a synergistic anti-cancer effect is generated through combination of cis-platinum and cis-platinum.
Owner:BEIJING CANCER HOSPITAL PEKING UNIV CANCER HOSPITAL

Lymphometastatic breast cancer treatment target and application thereof

The invention relates to the technical field of biological medicine, in particular to a lymphatic metastatic breast cancer treatment target and application thereof. The exosome piR-hsa-28212 disclosed by the invention can synergistically enhance VEGFC / VEGFR3 signal transduction, so that lymphatic vessel generation in breast cancer is promoted, and the potential of the exosome piR-hsa-28212 serving as a treatment target of lymphatic metastatic breast cancer is indicated. Besides, piR-hsa-28212 in the serum exosome of the breast cancer patient with lymphatic metastasis is obviously up-regulated, so that the piR-hsa-28212 can be used as a serum marker for predicting the lymphatic metastasis of the breast cancer, and has the advantages of noninvasive property, in-vitro stability, acquisition of samples and the like.
Owner:THE SECOND HOSPITAL OF SHANDONG UNIV

Thyroid tumor detection segmentation and lymphatic metastasis state diagnosis method and system

The invention provides a thyroid tumor detection segmentation and lymphatic metastasis state diagnosis method and system, and the method comprises the steps: collecting thyroid tumor ultrasonic images, carrying out the data cleaning and privacy processing of the ultrasonic images, and selecting the ultrasonic images with the image quality meeting a preset requirement, and building a basic database; marking a thyroid tumor outer contour of the ultrasonic image in the basic database and a minimum enclosing rectangle corresponding to the outer contour; taking the marked ultrasonic image as input, performing target detection by constructing a YOLOv8 detection model, and segmenting a tumor edge through an HRNet segmentation model; the cervical lymph node metastasis state of the thyroid tumor is judged through semi-quantitative parameter measurement and a Bayesian diagnosis classification model; and based on the trained YOLOv8 detection model, the trained HRNet segmentation model and the trained Bayesian diagnosis classification model, carrying out detection segmentation on a to-be-detected ultrasonic image, and judging a cervical lymph node metastasis state. Through the scheme, the tumor detection segmentation precision can be improved, rapid diagnosis of the thyroid tumor neck lymph node metastasis state is realized, and the manpower and material resource cost is saved.
Owner:TONGJI HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI TECH

Application of tageteoside and difacitinib or ponatinib in blocking esophageal squamous cell carcinoma progression

The invention provides application of combination of tageteoside and difacitinib or ponatinib to blocking of esophageal squamous cell carcinoma progression. The tageteoside is combined with an FAK inhibitor defacitinib or an Src family kinase inhibitor ponatinib, so that the metastasis of esophageal squamous carcinoma, especially lymphatic metastasis, can be inhibited, the growth of primary focus and metastatic focus esophageal squamous carcinoma cells can be inhibited, and a synergistic anti-cancer effect is achieved.
Owner:BEIJING CANCER HOSPITAL PEKING UNIV CANCER HOSPITAL

TNM staging management system of respiratory system

The invention discloses a TNM staging management system of a respiratory system. Comprising a chest CT image panoramic scanning module under an enhancement condition, a TMN stage prediction management unit, a lymph node acquisition unit, a tumor primary focus calculation unit, a lymph node model input unit, a region frame selection recognition unit, a lymph node recording unit, a lymph node metastasis judgment unit and an abnormal lymph node recognition unit. The output end of the pathological image panoramic scanning module is in communication connection with the input end of the TMN staging prediction management unit, and the beneficial effects are that the TMN staging prediction management unit is added, so that the conditions of primary tumor, lymphatic metastasis and distant metastasis are predicted, the later treatment is managed according to the predicted conditions, and the treatment efficiency is improved. A region frame selection identification unit is added and is used for carrying out state check processing on lymph nodes through a lymph node model and identifying existence of the lymph nodes and abnormal conditions of images.
Owner:SUZHOU YANGSHI TECH CO LTD +1

Marker and kit for diagnosing lymph node metastasis of early cervical cancer and application of marker and kit

The invention relates to the field of molecular diagnosis and tumor risk assessment, in particular to a marker combination and a kit for assessing the lymphatic metastasis risk of cervical cancer and application of the marker combination and the kit. The marker comprises a group of gene markers and a group of microbial markers, the gene markers comprise CARD9, MNX1AS2, MRAS, OLFML2A and RPS28, preferably, the gene markers further comprise at least one of CFL1P1 and GRASLND, and the microbial markers comprise microorganisms of the genus Dialister, the genus Catonella and the genus Campylobacter. The marker provided by the invention can be used for constructing an accurate risk assessment model, and can be used for developing a corresponding PCR (Polymerase Chain Reaction) kit, a mass spectrum or a chromatographic analysis system to realize metastasis risk prediction, curative effect assessment and new drug screening of cervical cancer patients.
Owner:ZHEJIANG CANCER HOSPITAL

K8s-based gastric cancer lymphatic metastasis pathology auxiliary diagnosis cloud platform

The invention discloses a K8s-based gastric cancer lymphatic metastasis pathology auxiliary diagnosis cloud platform, and belongs to the field of smart medical diagnosis platform technology application, the K8s-based gastric cancer lymphatic metastasis pathology auxiliary diagnosis cloud platform comprises a K8s cluster architecture part, a containerization application part and a network and security configuration part, and deploys and manages an AI model and Web services through a containerization technology; the utilization of computing resources is optimized by using a highly extensible and manageable architecture of K8s, and the AI computing accelerated by the GPU is supported at the same time. The platform integrates a data processing flow, a storage solution and a data monitoring design, and ensures the security and privacy protection of medical data. Besides, the platform supports real-time cooperation and interactive feedback, the accuracy and efficiency of diagnosis are remarkably improved through man-machine cooperation diagnosis, interactive optimization and actual combat teaching functions, and a powerful tool is provided for pathologists and researchers so as to improve the pathological diagnosis process and educational training.
Owner:THE SEVENTH AFFILIATED HOSPITAL SUN YAT SEN UNIV SHENZHEN

Application of IGF2BP2-m6A-VCAN-TLR2 signal axis in preparation of medicine for treating lymphatic metastasis of intrahepatic cholangiocarcinoma

ActiveCN122005811AOrganic active ingredientsInorganic active ingredientsNode metastasisInsulin-like growth factor-binding protein
The invention discloses application of an IGF2BP2-m6A-VCAN-TLR2 (Insulin-like Growth Factor 2BP2-m6A-VCAN-TLR2) signal axis in preparation of a medicine for treating lymphatic metastasis of intrahepatic cholangiocarcinoma. Aiming at the problems of unknown lymphatic metastasis mechanism and lack of effective targets of intrahepatic cholangiocarcinoma, the invention discovers and verifies that mRNA binding protein 2 of insulin-like growth factor 2 is modified by m6A to regulate and control the expression of pluripotent proteoglycan so as to activate a Toll-like receptor 2 signal, promote macrophages to secrete vascular endothelial growth factor C and drive a brand new pathway of lymphatic metastasis. Based on this, the invention provides an inhibitor targeting the signal axis, especially a small molecule compound 8010-8498. Experiments show that the compound can significantly inhibit migration, invasion and epithelial-mesenchymal transition of bile duct cancer cells, reduce macrophage secretion of vascular endothelial growth factors C, effectively inhibit tumor growth and lymphatic metastasis in a nude mouse popliteal lymph node metastasis model and a spontaneous bile duct cancer model, and present a synergistic effect when combined with gemcitabine and cis-platinum.
Owner:THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIV

BSA-MnO2 nanoprobe for identifying sentinel lymph node metastasis state of breast cancer and application of BSA-MnO2 nanoprobe

The invention belongs to the technical field of medicine, and relates to a BSA-MnO2 nanoprobe used for identifying breast cancer sentinel lymph node metastasis state, and applications thereof. The BSA-MnO2 nano probe is obtained by carrying out a reaction on BSA (Bovine Serum Albumin) and KMnO4; the BSA-MnO2 nanoprobe is injected into a human body as a magnetic resonance lymphatic vessel contrast agent, and in combination with a nuclear magnetic resonance scanning technology, a clear nuclear magnetic resonance structure image of a sentinel lymph node of a living body and quantitative parameters related to a lymphatic drainage function are successfully obtained, such as a nuclear magnetic enhancement signal value MES, a maximum nuclear magnetic enhancement signal value, a 3h relative lymph node clearance rate and the like. A sentinel lymph node metastasis assessment framework is formed through the parameters and can be used for identifying normal sentinel lymph nodes and breast cancer metastatic sentinel lymph nodes, and more importantly, the framework can be used for identifying breast cancer sentinel lymph node tiny metastasis and breast cancer sentinel lymph node large metastasis. And a new means is provided for noninvasive identification of the breast cancer sentinel lymph node metastasis state in clinical practice.
Owner:MEI HOSPITAL UNIV OF CHINESE ACAD OF SCI +1

Markers for predicting lymph node metastasis of colorectal adenocarcinoma in peripheral blood and application of markers

The invention belongs to the technical field of tumor lymph node metastasis, and particularly relates to a group of markers for predicting lymph node metastasis of colorectal adenocarcinoma in peripheral blood and application of the markers. The marker provided by the invention comprises glucose, interleukin-5 and NK (Natural Killer) cells. The markers have a close relationship with the lymphatic metastasis of the colorectal adenocarcinoma, increase of the glucose content and decrease of the NK cell proportion and the IL-5 content can reflect whether a patient suffers from the lymphatic metastasis of the colorectal adenocarcinoma or not, and the markers have high accuracy and can be used for assisting in predicting or judging the lymphatic metastasis condition of the colorectal adenocarcinoma. The detection reagent or kit can be used for preparing a reagent or kit for assisting in predicting or judging the lymph node metastasis condition of colorectal adenocarcinoma.
Owner:AFFILIATED HOSPITAL OF JIANGSU UNIV

Use of IGF2BP2-m6A-VCAN-TLR2 signal axis in preparation of drugs for treating intrahepatic cholangiocarcinoma lymph node metastasis

ActiveCN122005811BNode metastasisInsulin-like growth factor-binding protein
The application discloses an IGF2BP2-m6A-VCAN-TLR2 signal axis in the preparation of a drug for treating intrahepatic cholangiocarcinoma lymphatic metastasis. In view of the problems of unknown intrahepatic cholangiocarcinoma lymphatic metastasis mechanism and lack of effective target, the application finds and verifies a new pathway that from insulin-like growth factor 2 mRNA binding protein 2, m6A modification regulates the expression of multi-functional proteoglycan, and then activates Toll-like receptor 2 signal, promotes macrophage secretion of vascular endothelial growth factor C and drives lymphatic metastasis. Based on this, the application provides an inhibitor targeting the signal axis, in particular, a small molecule compound 8010-8498. Experiments show that the compound can significantly inhibit cholangiocarcinoma cell migration, invasion and epithelial mesenchymal transition, reduce macrophage secretion of vascular endothelial growth factor C, and effectively inhibit tumor growth and lymphatic metastasis in a naked mouse popliteal lymph node metastasis model and a spontaneous cholangiocarcinoma model. The compound presents a synergistic effect in combination with gemcitabine and cisplatin.
Owner:THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIV

Ferritin nanoprobe for targeting gastric cancer lymphatic metastasis as well as preparation method and application of ferritin nanoprobe

The invention discloses a ferritin nanoprobe for targeting gastric cancer lymphatic metastasis as well as a preparation method and application of the ferritin nanoprobe. According to the present invention, the fusion expression technology and the polycistron expression system are adopted to simultaneously display the two targeting peptide fragments on the cage-shaped surface of the ferritin without affecting the prokaryotic intracellular self-assembly characteristic, such that the method is simple and easy to perform, and the material innovation of the ferritin as the tumor targeting nano-probe is enriched. The three-target ferritin nano-probe constructed by the invention successfully fuses three targets of TfR1, CXCR4 and VEGFR3, endows ferritin with higher and wider affinity in combination with various gastric cancer tumor cells, and remarkably improves the targeting ability of the ferritin nano-probe for various gastric cancer tumor cells or tissues with different surface expression conditions; the difficulty of strong heterogeneity between cells / tissues in gastric cancer lymphatic metastasis diagnosis and treatment is effectively overcome.
Owner:NANFANG HOSPITAL OF SOUTHERN MEDICAL UNIV

Biomarker for lymphatic metastasis of cervical cancer and diagnostic application of biomarker

The invention provides a biomarker for diagnosing lymphatic metastasis of cervical cancer and application of the biomarker, and belongs to the field of medical diagnosis. According to the invention, three biomarkers of resting sulfydryl oxidase 1, paraoxonase 1 and keratin 6A for diagnosing lymphatic metastasis of cervical cancer are obtained through multivariate statistical analysis, difference screening, random forest, ROC analysis and other biosignal analysis methods. Based on the biomarker provided by the invention, a kit and the like for diagnosing lymphatic metastasis of cervical cancer are constructed, and the kit and the like are used for accurately judging whether lymphatic metastasis occurs in cervical cancer patients or not.
Owner:ZHEJIANG CANCER HOSPITAL +1

Application of ligustrazine in preparation of medicine for promoting lymphatic vessel neogenesis and in-vivo and in-vitro activation of VEGFC / VEGFR3 signal channel

The invention belongs to the technical field of natural medicines, and particularly relates to application of ligustrazine in preparation of medicines for promoting lymphatic neogenesis and in-vitro activation of a VEGFC / VEGFR3 signal channel. It is found for the first time that ligustrazine can remarkably enhance the proliferation and migration capacity of HLECs, the number of lymphatic vessels in an infarct marginal area can be increased after MI, inflammatory cell infiltration can be relieved, the content of VEGFC in serum can be increased, expression of lymphatic vessel neogenesis related protein and genes can be promoted, the heart function can be improved, and myocardial cell damage can be relieved. The invention also finds that ligustrazine can activate a VEGFC / VEGFR3 signal channel. The invention provides a new active ingredient for developing a lymphatic vessel regulator for promoting lymphatic vessel neogenesis, provides a new thought and method for cardiac tissue repair and function improvement after MI, and also provides a new modeling drug for constructing a lymphatic metastasis model by activating a VEGFC / VEGFR3 signal channel in vitro and evaluating the curative effect of the anti-lymphatic metastasis drug.
Owner:TIANJIN UNIV OF TRADITIONAL CHINESE MEDICINE

Application of medicine for inhibiting ZIP1 gene expression in inhibition of pancreatic cancer lymph node metastasis

The invention relates to application of a medicine for inhibiting ZIP1 gene expression in inhibiting pancreatic cancer lymph node metastasis. Pancreatic cancer cells can secrete S100A4, act on lymphatic endothelial cells (LEC) and up-regulate expression of ZIP1 molecules, glycolysis on the LEC is further up-regulated, lactic acid is generated, the lactic acid destroys expression of tight junction protein Claudin5 between the LEC, pancreatic cancer cells are promoted to enter lymphatic vessels and generate lymphatic metastasis, ZIP1 is used as a target spot, siRNA is constructed, or CRISPR / Cas9 technology is used, and the pancreatic cancer cells can be used for treating lymphatic metastasis. The expression of the lymphatic vessel ZIP1 gene is reduced, and the lymphatic metastasis of pancreatic cancer is blocked.
Owner:THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIV

Peptides translated from circular RNA-circ MYCBP2 and their application in regulating bladder cancer

The present invention discloses polypeptides translated from circular RNA-circMYCBP2 and their application in regulating bladder cancer, belonging to the field of tumor molecular biology. Taking the ability of circular RNA to encode short peptides or proteins as an entry point, the present invention screened out circMYCBP2, which is highly expressed in tissues of bladder cancer patients with positive lymphoma metastasis, and verified that its translation can translate the sequence MYCBP2-227aa shown in SEQ ID NO.1. At the same time, it also confirmed the promotion effect of MYCBP2-227aa on bladder cancer lymphatic metastasis, thereby revealing the biological role of MYCBP2-227aa in bladder cancer lymphatic metastasis, and providing a theoretical basis and scientific basis for MYCBP2-227aa as an early diagnostic marker and new treatment target for bladder cancer lymphatic metastasis.
Owner:SUN YAT SEN UNIV

Cyclic RNA-circ MYCBP2 translated polypeptide and application thereof in regulation and control of bladder cancer

The invention discloses a polypeptide translated by circular RNA-circMYCBP2 and application of the polypeptide in regulation and control of bladder cancer, and belongs to the field of tumor molecular biology. According to the application disclosed by the invention, circMYCBP2 which is highly expressed in tissues of a lymph cancer metastasis positive bladder cancer patient is screened by taking the capability of coding short peptides or proteins by circular RNA as an entry point, the translation of circMYCBP2 is verified, MYCBP2-227aa with a translation sequence as shown in SEQ ID NO.1, meanwhile, the promotion effect of MYCBP2-227aa on bladder cancer lymphatic metastasis is also verified, and the circMYCBP2 can be used for preparing the bladder cancer lymphatic metastasis. Therefore, the biological effect of the MYCBP2-227aa in the lymphatic metastasis of the bladder cancer is disclosed, and a theoretical basis and a scientific basis are provided for taking the MYCBP2-227aa as an early diagnosis marker and a new treatment target of the lymphatic metastasis of the bladder cancer.
Owner:SUN YAT SEN UNIV

Application of luteolin in sensitizing cisplatin in the preparation of drugs for the treatment of esophageal squamous cell carcinoma

The present invention relates to the use of luteolin to enhance the sensitization of cisplatin in the preparation of a drug for the treatment of esophageal squamous cell carcinoma. The present invention finds that luteolin can block the progression of esophageal squamous cell carcinoma cells in multiple aspects, including apoptosis induction, growth inhibition, and invasion inhibition. Luteolin can also significantly enhance the ability of cisplatin to inhibit the lymphatic metastasis of esophageal squamous cell carcinoma cells in a mouse model, demonstrating a significant synergistic effect between the two.
Owner:BEIJING CANCER HOSPITAL PEKING UNIV CANCER HOSPITAL

A biomarker for predicting the risk of lymph node metastasis in PTC and its application

The present invention belongs to the field of biomedical technology, and discloses a biomarker for predicting the risk of PTC lymph node metastasis and its application. 17 biomarkers TACSTD2, AGR2, CYP1B1, ATF3, KRT17, SPOCK3, DSC3, S100A9, PLAUR, F2R, LAMP5, SERPINE1, ASPN, HLA-DQB1, C1QC, MARCO, and LPL are used to form a gene panel for predicting the risk of PTC lymph node metastasis; a prediction model for PTC lymph node metastasis is constructed based on the LASSO regression algorithm; and the risk of PTC lymph node metastasis is calculated and scored. The gene panel composed of the biomarkers provided by the present invention is used for predicting the risk of PTC lymph node metastasis, a prediction model for PTC lymph node metastasis is constructed based on the LASSO regression algorithm, and the risk of PTC lymph node metastasis is scored and calculated, and an accurate assessment can be made on whether cervical lymph node metastasis occurs in the early stage of PTC.
Owner:THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIV

Application of luteolin glycoside combined with dacomitinib or ponatinib in blocking the progression of esophageal squamous cell carcinoma

The present invention provides the application of marigrin in combination with defactinib or ponatinib in blocking the progression of esophageal squamous cell carcinoma. The combination of marigrin with the FAK inhibitor defactinib or the Src family kinase inhibitor ponatinib can inhibit the metastasis of esophageal squamous cell carcinoma, especially lymphatic metastasis, and can inhibit the growth of esophageal squamous cell carcinoma cells in the primary focus and metastatic foci, and has a synergistic anti-cancer effect.
Owner:BEIJING CANCER HOSPITAL PEKING UNIV CANCER HOSPITAL

Biomarkers for diagnosing lymph node metastasis of cervical cancer and their applications

The present invention provides biomarkers for diagnosing lymph node metastasis of cervical cancer and their applications, belonging to the field of bio-detection technology. Through bioinformatics analysis methods such as multivariate statistical analysis, differential screening, random forest, and ROC analysis, the present invention obtains three biomarkers, namely, quiescent thiol oxidase-1, paraoxonase 1, and keratin 6A, for diagnosing lymph node metastasis of cervical cancer. Based on the biomarkers of the present invention, kits for diagnosing lymph node metastasis of cervical cancer are constructed, etc., for accurately judging whether lymph node metastasis has occurred in cervical cancer patients.
Owner:ZHEJIANG CANCER HOSPITAL +1

Early gastric cancer lymphatic metastasis risk auxiliary inspection method based on collagen fiber morphological structure fusion characteristics

The invention discloses an early gastric cancer lymphatic metastasis risk auxiliary inspection method based on collagen fiber morphological structure fusion characteristics. An extracellular matrix collagenous fiber image of a gastric tumor tissue is obtained in an unmarked second harmonic imaging mode, and automatic early gastric cancer lymphatic metastasis risk assessment can be realized by performing quantitative calculation and analysis of multivariate parameter characteristics on morphological structure characteristics of the collagenous fiber. According to the method, the morphological structure characteristics of the gastric tumor collagenous fibers can be intuitively displayed through a pixel-level morphological characterization method, and the information readability is enhanced. According to the method, the complementarity of the morphological structure characteristics of the collagenous fibers of the gastric tumor tissue is remarkably improved through multi-element parameter characteristic characterization, and the accuracy of lymphatic metastasis risk assessment is further improved. According to the method, an early gastric cancer lymphatic metastasis risk specificity index is formed based on the multi-element morphological characteristics of collagenous fibers, and a local focus area can be quantitatively and intuitively displayed.
Owner:ZHEJIANG UNIV

Effect of circSEMA3C-coded SEMA-123aa in targeted therapy of lymphatic metastasis of bladder cancer

The invention discloses an effect of circSEMA3C coding SEMA-123aa in targeted therapy of lymphatic metastasis of bladder cancer, and belongs to the technical field of biological medicine. According to the application disclosed by the invention, circRNA-circSEMA3C up-regulated in bladder cancer tissues is screened out through high-throughput sequencing by taking a circRNA coding product for driving bladder cancer lymphatic metastasis as an entry point, and it is proved that the circSEMA3C-123aa coded by the circSEMA3C is positively correlated with bladder cancer lymphatic metastasis, so that bladder cancer lymphatic neogenesis and lymphatic metastasis can be promoted, and bladder cancer lymphatic metastasis can be promoted. Therefore, the biological action of the SEMA3C-123aa in the lymphatic metastasis of the bladder cancer is disclosed, and a theoretical basis and a scientific basis are provided for the SEMA3C-123aa serving as an early diagnosis marker and a novel treatment target of the lymphatic metastasis of the bladder cancer.
Owner:SUN YAT SEN UNIV

Device, method, system and application thereof for diagnosing lymphatic metastasis of cervical cancer

The present invention provides a device, method, system and application thereof for diagnosing lymphatic metastasis of cervical cancer, belonging to the field of medical evaluation technology. The present invention obtains three biomarkers, namely, resting sulfhydryl oxidase-1, paraoxonase 1 and keratin 6A, for evaluating lymphatic metastasis of cervical cancer through bioinformatics analysis methods such as multivariate statistical analysis, difference screening, random forest, ROC analysis, etc. Based on the biomarkers of the present invention, an evaluation device, computer execution method, computer system, kit, etc. for evaluating lymphatic metastasis of cervical cancer are constructed to accurately determine whether lymphatic metastasis occurs in patients with cervical cancer.
Owner:ZHEJIANG CANCER HOSPITAL +1

LYP-1 targeted composite nano-material for diagnosis and treatment of pancreatic cancer lymphatic metastasis and application of LYP-1 targeted composite nano-material

The invention belongs to the technical field of clinical diagnosis and treatment, and provides an LYP-1 targeted composite nano-material for diagnosis and treatment of pancreatic cancer lymphatic metastasis and application of the LYP-1 targeted composite nano-material for diagnosis and treatment of pancreatic cancer lymphatic metastasis, the LYP-1 targeted composite nano-material for diagnosis and treatment of pancreatic cancer lymphatic metastasis comprises a LyP-1 polypeptide modified nano-carrier and a loaded diagnosis and treatment agent, the diagnosis and treatment agent is a treatment drug or a diagnosis marker aiming at pancreatic cancer lymphatic metastasis; through the LyP-1 polypeptide modified nano-carrier, efficient targeting of the pancreatic cancer lymphatic metastasis part is realized; as a targeting molecule, the LyP-1 polypeptide can specifically recognize and bind to pancreatic cancer lymphatic metastatic cells, so that the aggregation concentration of the nano material at a focus part is improved, the treatment effect is enhanced, and the damage to normal tissues is reduced.
Owner:蒋涛

Application of lncRNA MAGE-A10 coding short peptide in regulating lymphatic metastasis of bladder cancer and targeted therapy for patients

This invention discloses the application of lncRNA MAGE-A10-encoded short peptide in regulating lymph node metastasis and targeted therapy in bladder cancer, belonging to the field of biomedical technology. This invention focuses on the coding ability of long non-coding RNAs, using high-throughput sequencing and bioinformatics algorithms to screen for lncRNA MAGE-A10, which is highly expressed in lymph node metastasis-positive bladder cancer tissues. The coding ability was verified by predicting open reading frames, constructing expression vectors, and synthesizing specific antibodies. The encoded short peptide MAGE-A10-44aa was positively correlated with lymph node metastasis in bladder cancer and poor patient prognosis, and also promoted lymphangiogenesis and lymph node metastasis in bladder cancer. This confirms the biological role of the MAGE-A10-44aa short peptide in bladder cancer lymph node metastasis, providing a potential target for bladder cancer treatment.
Owner:SUN YAT SEN UNIV

Nanoparticle chip and application thereof in screening metabolic marker combination

The invention discloses an FELDI nano-particle chip kit and application thereof in screening metabolic marker combinations, and relates to the technical field of biology. The FELDI nano-particle chip kit comprises a methanol solution and a microarray chip which is pre-coated with iron nano-particles, the kit is used for dewaxing tissue slices, the tissue slices are immersed in a methanol solution and incubated to obtain a sample, and the sample is applied to a microarray chip pre-coated with iron nanoparticles; a colorectal cancer tissue metabolism fingerprint database is constructed, and specific metabolism markers combined with L-cysteine, adipic acid, decanoic acid, azelaic acid, pentadecanoic acid, stearic acid and isolithocholic acid are screened. The invention develops an unmarked iron nanoparticle enhanced laser desorption ionization mass spectrometry technology platform, and the small molecule metabolites can be directly and efficiently captured and ionized from the formalin-fixed paraffin-embedded CRC primary tissue section. And screening out a specific small molecule metabolism marker combination for distinguishing lymphatic metastasis and non-metastasis.
Owner:SHANGHAI JIAOTONG UNIV

Role of circSEMA3C encoding SEMA-123aa in targeted therapy of bladder cancer lymph node metastasis

The present invention discloses the role of SEMA-123aa, encoded by circSEMA3C, in the targeted treatment of bladder cancer lymphatic metastasis, belonging to the field of biomedicine technology. The present invention uses the circRNA encoding product that drives bladder cancer lymphatic metastasis as the starting point, screens out circRNA-circSEMA3C that is upregulated in bladder cancer tissue through high-throughput sequencing, and confirms that SEMA3C-123aa, encoded by circSEMA3C, is positively correlated with the occurrence of bladder cancer lymphatic metastasis and can promote bladder cancer lymphangiogenesis and lymphatic metastasis, thereby revealing the biological role of SEMA3C-123aa in bladder cancer lymphatic metastasis and providing a theoretical basis and scientific basis for SEMA3C-123aa as an early diagnostic marker and new treatment target for bladder cancer lymphatic metastasis.
Owner:SUN YAT SEN UNIV